INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT.

Size: px

Start display at page:

Download "INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT."

Archibald Bryan
5 years ago
Views:

1 INTERNATIONAL MASTERCLASS ON LIVER DISEASE IN HIV VILNIUS, LITHUANIA 18 SEPTEMBER 2019 (TBC) REQUEST FOR SUPPORT

2 INTRODUCTION Liver disease in the setting of HIV is increasingly presenting a major concern for HIV providers. While the availability of a cure for HCV has made a huge impact, there is still an urgent need for information on drug-drug interaction and the management of the HIV patient after the cure of HCV. In addition, hepatotoxicity, fatty liver disease and other viral hepatitides remain major management issues. To address this unmet need, we plan to provide a one-day Masterclass on Liver Disease in HIV, preliminarily scheduled to take place prior to the 5th edition of the Central and Eastern European Meeting on Viral Hepatitis on HIV in September 2019 in Vilnius, Lithuania. At the International Workshop of Co-infection: HIV and Hepatitis, last edition of which took place in May 2018, we have had pre-meeting educational course in liver disease for many years. These lectures are always the best attended and ranked the highest among attendees. We anticipate that this one day course will be equally well attended. Given the timing and location, we expect a large audience from CEE countries. However, the masterclass is open to international participants. We will provide lectures by world experts and attendees will have the opportunity to interact with our speakers. CHAIRS Marion Peters, MD University of California, San Franciso USA This highly interactive masterclass is specially designed for practicing clinicians and early career investigators. The masterclass will provide updates on NAFLD, NASH, Hep B, Hep C, care after cure, cirrhosis, end stage liver disease, etc., and will help professionals sift through the overwhelming and over-saturated landscape of information on the above-mentioned topics. In order to be able to deliver the first edition of this masterclass, we depend on corporate support. Support of this workshop will provide you with the opportunity to demonstrate your commitment to the novel, ongoing research taking place in the field of liver disease in HIV+ individuals. Jürgen Rockstroh, MD University of Bonn, Germany We look forward to welcoming you at this first edition of the Masterclass, and we hope we can count on your support. 2

NEEDS ASSESSMENT With the advances in antiretroviral therapy, people living with HIV (PLWH) are seeing large improvements in longevity, which comes with the risk of age-related diseases and other

3 NEEDS ASSESSMENT With the advances in antiretroviral therapy, people living with HIV (PLWH) are seeing large improvements in longevity, which comes with the risk of age-related diseases and other co-morbidities. Among PLWH, liver diseases are one of the major causes for non-hiv related morbidity and mortality.1 Liver diseases can lead to cirrhosis and can be caused by a range of conditions that affect the liver, such as viral hepatitis, malignant conditions, alcoholic related liver diseases and non-alcoholic fatty liver diseases (NAFLD), among others. One of the main causes of liver diseases among PLWH is co-infection; either with hepatitis B virus (HBV), seen in 5%-25% of PLWH; and/or hepatitis C virus (HCV) co-infection, seen in ca. 30% of PLWH.1 Another common condition is non-alcoholic fatty liver disease (NAFLD), which is increasingly seen in PLWH.2 Due to aging, metabolic disorders and obesity, 30-40% of PLWH show steatosis.2 To prevent progression of liver diseases and ensure optimal treatment and care for patients, early diagnosis and knowledge of most effective treatment options are crucial. In many regions there is no sufficient awareness among clinicians of conditions affecting the liver, and no adequate knowledge on optimal screening and latest treatment options. Hence, it is crucial for clinicians caring for PLWH to learn more about liver diseases and their causes, and to be able to identify patients at risk and to optimize screening, diagnosis and treatment. Currently, there is no dedicated educational program on liver diseases in HIV for clinicians and HCPs. Considering the many advances and updates in treatment guidelines in the field, it is vital to educate clinicians on the challenges and opportunities in treating and caring for patients with liver diseases in routine practice. Through this educational masterclass we will enhance knowledge transfer and provide a platform for exchange of experiences to help clinicians gain confidence in their clinical practice. By addressing urgent needs in different topics related to liver diseases in HIV this course will build capacity among participants to ultimately help them to optimize treatment for their patients. TARGET AUDIENCE Practicing clinicians; Early career investigators; Other HCPs caring for HIV patients who will benefit from more knowledge on liver diseases in HIV patients. ESTIMATED NUMBER OF PARTICIPANTS participants TARGET REGION This educational masterclass will be targeting an international audience. The first edition is preliminarily scheduled to take place prior to CEE Meeting 2019 in Vilnius, Lithuania on 18 September 2019 (TBC). We therefore expect a large audience from Central and Eastern European countries. However, the masterclass is open to international participants. 1. MB Kaspar, RK Sterling. Mechanisms of liver disease in patients infected with HIV. BMJ Open Gastroenterol. 2017; 4(1): e Published online 2017 Oct M Lemoine, L Serfaty, J Capeau. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management. Curr Opin Infect Dis Feb;25(1):

4 OBJECTIVES, OUTCOMES, FORMAT Meeting objectives The objectives of this educational masterclass will be to: Increase awareness and knowledge among clinicians and other HCPs on liver diseases in HIV, treatment guidelines, recent scientific advances in the field and their relevance to clinical practice; Provide a platform for discussion and exchange of the experiences in hepatitis and liver diseases relevant to routine clinical practice; Build capacity and increase confidence among HCPs in the field of liver diseases to optimize patient care. Learning objectives After participating in this masterclass, delegates will be able to: Summarize recent scientific advances in the treatment of NAFLD, NASH, viral hepatitis, cirrhosis and end stage liver disease and their relevance to clinical practice; Identify the optimal treatment strategy for their patients, considering drug-drug interactions and available guidelines. Expected Impact /Outcome We expect that the Masterclass on Liver Diseases in HIV will contribute greatly to capacity building among clinicians and other HCPs treating people living with HIV. Clinicians will gain awareness and knowledge on general advancements and treatment options in both infectious and non-infectious liver diseases. They will learn first-hand about the expanding therapeutic options that are available to them for clinical use. Through interactive elements and case studies they will learn to apply their knowledge and gain confidence for their practice. The educational masterclass will ultimately help them optimize their patient management skills. Learning assessment method To assess the meeting, Virology Education provides each delegate with a detailed feedback form to assess the speakers, whether or not the meeting objectives were met, their intent to change, the rationale behind their motivation to attend, the general logistics of the meeting, and more. All the questions are then fully analyzed and a comprehensive report is created and shared with the committee members. These reports help us to better understand our delegates needs and how to improve the meeting in the future. FORMAT This highly interactive one-day masterclass will consist of state-of-the-art plenary lectures, insightful clinical case presentations, and Q&A sessions. The program will be designed to allow for maximum discussion and interaction between expert faculty and delegates and specifically address gaps in knowledge in clinical care. Meals, breaks and the social events allow for more informal discussions and networking among attendees. BLENDED LEARNING We aim to design a blended learning program for participants which will transform the course into an even more interactive and engaging educational experience. The blended learning approach will consist of a series of activities such as: pre-meeting activities (knowledge assessments, quizzes, polls, small assignments), as well as postmeeting activities such as a post test, evaluation and long-term assessment of knowledge. ACCREDITATION We aim to submit an application to the EACCME for CME accreditation of this event. For a maximum response rate, we invite the chairs of each session to encourage the participants to take a few minutes and complete the feedback forms. We are also introducing a web-based application to allow participants access to the feedback forms electronically. 4

5 ENDURING MATERIALS The live sessions will be recorded and made available on Virology Education s website. Interested participants who cannot attend the live meetings can in this way follow the presentations online on their own time. We will also have the opportunity of offering the recorded sessions in the form of an online course to those who cannot attend the live course. Registration will be made available for online course participants and a pre- and post-testing will be implemented for those interested in obtaining CME credits. 5

SPONSORSHIP SPONSOR BENEFITS As a sponsor of the Masterclass Liver Diseases in HIV, you will have the unique opportunity to connect with clinicians and other HCPs and get an insight on their

6 SPONSORSHIP SPONSOR BENEFITS As a sponsor of the Masterclass Liver Diseases in HIV, you will have the unique opportunity to connect with clinicians and other HCPs and get an insight on their knowledge and experiences treating patients with liver diseases. Engage with potential collaborators and experts and discuss the latest advancements and information in the field of liver diseases in HIV. Sponsoring this program will give you the following benefits: Visibility Prominent placement of your logo on conference materials (online and offline) Pre-event marketing and branding through: - Banners posted on the homepage of the website - Traffic generation to your website via the conference website - Your logo placed on monthly newsletters which are delivered to thousands of opt-in subscribers - Electronic advertising posted on several calendars linked to the event website Contribution to the program Participate in discussions Commercial benefits Exhibition opportunities Promotion option to display marketing materials such as pamphlets, flyers, postcards and other materials on the marketing table (subject to approval) [if available] Privileges Your contribution entitles you to the following privileges: Exhibition space Symposia inclusion Complimentary registrations to the event to increase your networking opportunities Other benefits described under various sponsorship levels 6

7 SPONSORSHIP CONFERENCE PARTICIPATION GRANTS The conference participation grants (CPG) provide healthcare professionals with the opportunity to attend a conference they would otherwise be unable to attend due to financial restrictions. All applications include a CV, a motivation letter, and potentially an abstract (requirements vary depending on the workshop). These are submitted via an independent CPG portal and are evaluated against the assessment criteria using a robust, impartial and independent peer review process. This process will ensure that the most qualified candidates will receive CPGs. The grants are supported by the financial contributions allocated by the sponsor, who has no control, influence, or involvement in the selection process of the CPG candidates whatsoever. Priority is given to applicants who have actively participated in original research or scientific work that is being presented at the meeting and/or those who will profit most from participating in order to improve their daily clinical management. These grants help defray costs for registration, travel and accommodation for delegates and foster their ability to form valuable professional networks and develop vital collaborations. Conference participation grant applications will be solicited, selected and awarded by an expert Grant Review Committee. Please note that the TITANIUM, PLATINUM and GOLD support levels will reduce the costs for conference participation grants. 7

8 ABOUT US VIROLOGY EDUCATION With over 20 years of experience, Virology Education is a leading provider of innovative scientific and educational programs worldwide. Our programs provide excellent platforms for scientific exchange, education and knowledge-sharing tailored to the needs of healthcare professionals in the fields of infectious diseases, pharmacology, liver disease, and more. Our activities include the initiation and organization of real-time and online platforms for international exchange, knowledge-sharing and education for medical professionals. We have developed long-standing collaborations with world-leading experts and work together with other important stakeholders to achieve the greatest impact for our programs and to provide top quality scientific content. Our programs range from international abstract-driven workshops to small and large scale educational series, masterclasses, advisory boards, expert rounds, satellite symposia, and more. Biltstraat BJ Utrecht The Netherlands info@virology-education.com Goda Adomonis, MA Senior Project manager goda@vironet.com More than 50 programs are planned for 2018 in more than 30 different cities around the globe! Johanna Schaeffer, PhD Medical manager johanna@vironet.com OUR IMPACT IN programs 4,187 participants 2,277 accepted abstracts 59% returning participants 28,000+ opt in subscribers

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT.

1 ST EUROPEAN. NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT. 1 ST EUROPEAN NASH Workshop BARCELONA, SPAIN 8-9 MARCH 2019 REQUEST FOR SUPPORT NEEDS ASSESSMENT NEEDS ASSESSMENT Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease affecting 25 % of